HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and maintained a price target of $65.
August 01, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Halozyme Therapeutics and maintained a price target of $65, indicating continued confidence in the company's performance.
The reiteration of a Buy rating and maintenance of a $65 price target by HC Wainwright & Co. suggests strong confidence in Halozyme Therapeutics' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100